We are live on ! Find out more
LBA

Letko, Brosseau & Associates Portfolio holdings

AUM $6.77B
1-Year Est. Return 38.11%
This Fund
S&P 500
This Quarter Est. Return
+14.88%
1 Year Est. Return
+38.11%
3 Year Est. Return
+83.35%
5 Year Est. Return
+109.01%
10 Year Est. Return
+317.99%
AUM
$5.55B
AUM Growth
+$508M
Cap. Flow
-$116M
Cap. Flow %
-2.08%
Top 10 Hldgs %
33.64%
Holding
105
New
4
Increased
21
Reduced
62
Closed
8

Top Buys

Rank Stock Value
1
EFXT
Enerflex
EFXT
+$40.9M
2
FDX icon
FedEx
FDX
+$25.6M
3
GSK icon
GSK
GSK
+$21.1M
4
RCI icon
Rogers Communications
RCI
+$18.2M
5
SAVE
Spirit Airlines, Inc.
SAVE
+$9.45M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$25.4M
2
CVE icon
Cenovus Energy
CVE
+$24.7M
3
MRK icon
Merck
MRK
+$21.1M
4
CNQ icon
Canadian Natural Resources
CNQ
+$20.9M
5
SBS icon
Sabesp
SBS
+$19M

Sector Composition

Rank Sector Weight
1 Financials 29.2%
2 Communication Services 16.02%
3 Energy 12.23%
4 Materials 11.6%
5 Technology 9.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SPRO icon
101
Spero Therapeutics
SPRO
$65.8M
-73,659
Closed -$147K
BCEL
102
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
-17,800
Closed -$28K
ONCR
103
DELISTED
Oncorus, Inc.
ONCR
-59,150
Closed -$50K
IMV
104
DELISTED
IMV Inc. Common Shares
IMV
-17,000
Closed -$88K
MYOV
105
DELISTED
Myovant Sciences Ltd.
MYOV
-63,204
Closed -$1.14M

Similar funds

Letko, Brosseau & Associates's Q4 2022 Portfolio in Review

As of Q4 2022, Letko, Brosseau & Associates held 105 positions worth $5.55B, up 10% from $5.04B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Letko, Brosseau & Associates's Q4 2022 filing shows 4 new, 21 increased, 62 reduced and 8 closed positions. Its largest new stake was Enerflex: 7,046,611 shares worth $44.4M. The largest sale was Gilead Sciences, an estimated $25.4M.

By sector, the portfolio is most concentrated in Financials at 29% of assets, down from 30% a quarter earlier, followed by Communication Services and Energy.

  • Letko, Brosseau & Associates's largest Q4 2022 buy was Enerflex: 7,046,611 shares worth $44.4M.
  • Letko, Brosseau & Associates added most to GSK in Q4 2022, an estimated $21.1M increase.
  • Letko, Brosseau & Associates's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $25.4M.
  • Letko, Brosseau & Associates fully exited Fluor in Q4 2022, selling an estimated $6.73M.
  • Letko, Brosseau & Associates's ten largest holdings make up 34% of its $5.55B portfolio in Q4 2022.
  • Letko, Brosseau & Associates opened 4 new positions and closed 8 in Q4 2022.
  • Letko, Brosseau & Associates's portfolio value rose 10% quarter-over-quarter to $5.55B.

Based on Letko, Brosseau & Associates's 13F filing for Q4 2022, filed 10 Feb 2023.